MAP2K7 and melanoma: We and others have recently shed new light on the immunomodulatory effects of CDK4/6i, both alone and in combination with current melanoma standard-of-care therapies, including ICI (targeting PD-1, PD-L1, and CTLA-4) and targeted BRAF and MEK therapies9,12,15–19.